photo of Louise Rodino-Klapac

Louise Rodino-Klapac, PhD

Senior Vice President, Gene Therapy

“I’m here to bring gene therapy to life. We have to be creative; we need to transform the paradigm. There isn’t a path to guide us. We’re making the path.”

Dr. Louise Rodino-Klapac joined Sarepta in June 2018. Renowned for her work in molecular genetics and gene therapy, she was head of the Laboratory for Gene Therapy Research at Nationwide Children’s Hospital before joining Sarepta. 

Louise was attracted to Sarepta because of the urgency of its goal to turn investigational programs into reality.

“That’s why I’m here. To bring gene therapy to life. We have to be creative; we need to transform the paradigm. There isn’t a path to guide us. We’re making the path.”

At Nationwide Children’s Hospital, her efforts drove the decade-long research project that led to micro-dystrophin gene therapy, Sarepta’s investigational treatment for Duchenne muscular dystrophy. She is also the inventor of 5 of Sarepta’s limb-girdle muscular dystrophy programs, which are part of our gene therapy engine approach to treating multiple genetic diseases. Overall, her work has led to 11 investigational new drug applications.

Louise’s interest in genetics started in junior high school, when the idea of genetic medicine was still largely theoretical. “I made a decision then that this is what I wanted to do for the rest of my life, and essentially I’ve never wavered.” 

The evidence of her focus can be seen in numerous scientific achievements, including field-advancing, peer-reviewed papers, multiple awards, and her appointment as a National Institutes of Health Fellow.

Louise holds a BS in biology from Kings College and a PhD in molecular genetics from Ohio State University.